5-Fluorouracil, Adriamycin, Cyclophosphamide (FAC) vs. 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Metastatic Breast Cancer
Massimo LopezPaola PapaldoLuigi Di LauroPatrizia ViciSilvia CarpanoEttore Conti
Abstract
94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46% versus 44% to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm.
Metrics
Citation History
Topics
Related Documents
5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC Combination) in Advanced Breast Cancer
C. ZamagniA. MartoniL. ErcolinoMaría V. BaroniS TannebergerF Pannuti
Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) for Breast Cancer
John E. MbueDominic A. SolimandoJ. Aubrey Waddell
FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy
G. CatimelFranck ChauvinJean‐Paul GuastallaPaul RebattuPierre BironM. Clavelt
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer
Henrik LindmanGunnar ÅströmJohan AhlgrenKenneth VillmanCarl BlomqvistPeter NygrenJonas Bergh
Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer
Tetsuro KobayashiHiroki KoyamaTakahiro OkaTadaki YasumuraNorimichi KanYuichi TakatsukaMasakuni NoguchiKen MorimotoTakaichiro SuzukiTakayoshi TobeTakesada Mori